Pharsight

1. Lamictal Odt patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7919115	GLAXOSMITHKLINE LLC	Orally disintegrating tablet compositions of lamotrigine	Jan, 2029 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8840925	GLAXOSMITHKLINE LLC	Orally disintegrating tablet compositions of lamotrigine	Jul, 2028 (4 years from now)
US9339504	GLAXOSMITHKLINE LLC	Orally disintegrating tablet compositions of lamotrigine	Jul, 2028 (4 years from now)

Drugs and Companies using LAMOTRIGINE ingredient

Market Authorisation Date: 08 May, 2009

Treatment: Lamictal is an antiepileptic drug (aed) indicated for: epilepsy-adjunctive therapy in patients greater than or equal to 2 years of age: (1.1) partial seizures primary generalized tonic-clonic seizures

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
25 mg, 50 mg, 100 mg, and 200 mg	21 Dec, 2009	1	15 Jul, 2013	04 Jan, 2029	Deferred

Strength	Dosage	Availability
25MG	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription
50MG	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription
100MG	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription
200MG	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription

LAMICTAL ODT family patents

2. Lamictal Xr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9144547	GLAXOSMITHKLINE LLC	Oral dosage form for controlled drug release	Sep, 2023 (6 days ago)
US8637512	GLAXOSMITHKLINE LLC	Formulations and method of treatment	Jun, 2028 (4 years from now)

Drugs and Companies using LAMOTRIGINE ingredient

Market Authorisation Date: 29 May, 2009

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg	12 Feb, 2014	1		14 Jun, 2028	Extinguished

Strength	Dosage	Availability
25MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
50MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
100MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
200MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
250MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
300MG	TABLET, EXTENDED RELEASE;ORAL	Prescription